Current role of thalidomide in cancer treatment

Current Opinion in Oncology

Volumn 12, Issue 6, 2000, Pages 564-573

  Thomas, Deborah A ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ALOPECIA; BONE MARROW SUPPRESSION; CACHEXIA; CANCER THERAPY; DIARRHEA; DRUG EFFECT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; LEAN BODY WEIGHT; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TERATOGENICITY; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; GRAFT VS HOST DISEASE; HUMANS; NEOPLASMS; THALIDOMIDE;

EID: 0034508512     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200011000-00009     Document Type: Review

References (95)

1. Thalidomide increases both REM and stage 3-4 sleep in human adults: A preliminary study
2. The saga of thalidomide (concluded): Neuropathy to embryopathy, with case reports of congenital anomalies
3. Thalidomide in the treatment of lepra reaction
4. Thalidomide in dermatology: New indications for an old drug
5. Thalidomide treatment of choice for aphthous ulcers in patients seropositive for HIV
6. The emerging role of thalidomide therapy in HIV-infected patients
7. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection
8. Clinical experiences with thalidomide in patients with cancer
9. Thalidomide in the treatment of advanced cancer
10. Tumor angiogenesis: Therapeutic complications
11. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma
12. Tumor angiogenesis: A new significant and independent prognostic indicator in early stage breast carcinoma
13. Relation of neovascularization to metastasis of non-small-cell lung cancer
14. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
15. Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma
16. Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma
17. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas
18. Tumor angiogenesis correlates with lymph node metastasis in invasive bladder cancer
19. Expression of vascular endothelial cell growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer
20. Extent of tumor vascularization correlates with the prognosis and hematogenous metastasis in gastric carcinomas
21. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma
22. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
23. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
24. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
25. Angiognesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density (MVD) in bone marrow biopsies
26. Evaluation and clinical correrations of microvessel density in myelofibrosis with myeloid metaplasia
27. Plasma levels of VEGF and bFGF in various leukemias and their correlation with angiogenesis
28. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
29. Elevated VEGF serum levels in idiopathic myelofibrosis
30. Thalidomide is an inhibitor of angiogenesis
31. Effects of thalidomide and related metabolites in a mouse corneal mode of neovascularization
32. Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies
33. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
34. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
35. Factors promoting tumor angiogenesis
36. Tumor necrosis factor and its receptors in human ovarian cancer: Potential role in disease progression
37. Expression of tumor necrosis factor α and its receptors in carcinoma of the breast
38. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
39. Thalidomide exerts its inhibitory action on tumor necrosis factor by enhancing mRNA degradation
40. Binding of thalidomide to 1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor production
41. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumor agent 5,6-dimethylxanthenone-4-acetic acid: Concomitant reduction of serum tumor necrosis factor-alpha and enhancement of anti-tumor activity
42. Inhibition of IL-12 production by thalidomide
43. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concananvalin-A, staphylococcal enterotoxin A, and purified protein derivative
44. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells
45. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
46. The immunosuppressive drug thalidomide induces T helper cell type (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures
47. Immunosuppressive properties of thalidomide: Inhibition of in-vitro lymphoctye proliferation alone and in combination with cyclosporin or FK506
48. Thalidomide effect on T cell subsets as a possible mechanism of action
49. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
50. Thalidomide and the immune system: Simultaneous up- and down-regulation of different integrin receptors on human white blood cells
51. Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine- and endotoxin-activated endothelium
52. Induction of morphologic differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites
53. Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites
54. Pharmacology of thalidomide
55. Thalidomide neuropathy: A clincal, electrophysiological, and histologic follow-up study
56. Thalidomide neurotoxicity
57. Thalidomide-induced peripheral neuropathy: Effect of serum factor on nerve cultures
58. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone
59. S.T.E.P.S.™: A comprehensive program for controlling and monitoring access to thalidomide
60. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
61. Phase II study of thalidomide as an anti-angiogenic agent in the treatment of recurrent glioblastoma multiforme (GBM)
62. A phase I/II study of carboplatin and thalidomide in recurrent glioblastoma multiforme
63. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titer
64. Phase I trial of thalidomide in AIDS-related Kaposi's sarcoma
65. A pahse II study of oral thalidomide in patients with AIDS-related Kaposi's sarcoma (KS)
66. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
67. Thalidomide treatment of metastatic renal cell carcinoma
68. A randomized phase II study of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer
69. Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells
70. Phase II trial of Thalidomid (thalidomide) for treatment of non-resectable hepatocellular carcinoma (HCC)
71. Pilot trial of thalidomide post-autologous peripheral blood progenitor cell transplantation in patients with metastatic breast cancer
72. Phase II trial of thalidomide in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCHN)
73. Pilot and safety trial of carboplatin, paclitaxel and thalidomide in advanced non-small cell lung cancer
74. The FDA experience on the use of halidomide in advanced malignancies
75. Antitumor activity of thalidomide in refractory multiple myeloma
76. Thalidomide (T) in the management of multiple myeloma (MM): The Arkansas experience in > 300 patients (Pts) with single agent (SA) and combination therapy (CT)
77. Thalidomide: Therapeutic potential in hematologic malignancies
78. Thalidomide for resistant and relapsing myeloma
79. Thalidomide alone or with dexamethasone for multiple myeloma
80. Clinical experience with thalidomide in multiple myeloma: Phase II trial results in refractory disease and ongoing studies
81. Activity of thalidomide in Waldenstrom's macroglobulinemia
82. Encouraging improvement in cytopenias of patients with myelodysplastic syndromes (MDS) with thalidomide
83. Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders
84. Thalidomide as antiangiogenesis therapy (Rx) in refractory or relapsed leukemias
85. Thalidomide anti-angiogenesis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF)
86. Paradoxical effect of thalidomide prophylaxis on chronic graft-versus-host disease
87. Thalidomide for treatmeznt of chronic graft-versus-host-disease
88. Thalidomide as salvage therapy for chronic graft-versus-host disease
89. Thalidomide induced cessation of weight loss and improved sleep in advanced cancer patients with cachexia
90. Thalidomide for distressing night sweats in advanced malignant disease
91. Thalidomide for night sweats in patients with advanced cancer
92. Thalidomide in hematologic malignancies: Future directions
93. Amino-substituted thalidomide analogs: Potent inhibitors of TNF-alpha production
94. Immunomodulation by thalidomide and thalidomide analogues
95. Thalidomide and pentoxifylline prevent the development of chronic cardiomyopathy provoked by doxorubicin in rats without inhibiting its antitumoral effect